Report #2825919

Received Feb 12, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: —
Recovered: Recovered
Vaccinated: May 1, 2024
Onset: Aug 1, 2024
Days to onset: 92
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	1	UNK	—

Symptoms (1)

Herpes zoster

Symptom narrative

Patient developed shingles after first dose administered; This non-serious case was reported by a nurse via sales rep and described the occurrence of shingles in a female patient who received Herpes zoster (Shingrix) for prophylaxis. In MAY-2024, the patient received the 1st dose of Shingrix. In AUG-2024, between 2 and 4 months after receiving Shingrix, the patient experienced shingles (Verbatim: Patient developed shingles after first dose administered). The outcome of the shingles was resolved. It was unknown if the reporter considered the shingles to be related to Shingrix. It was unknown if the company considered the shingles to be related to Shingrix. Additional Information: GSK Receipt Date: 10-FEB-2025 The nurse reported that patient developed shingles after administration of first dose of Shingrix vaccine The patient developed shingles in August 2024 before receiving second dose.